HOME >> BIOLOGY >> NEWS
Story tips from the Department of Energy's Oak Ridge National Laboratory, April 2004

To arrange for an interview with a researcher, please contact the Communications and Community Outreach staff member identified at the end of each tip.

PROTECTIVE GEAR — High-tech for first responders . . .

First responders could minimize the risk to themselves and do their jobs more effectively if they were wearing a protective suit proposed by a team led by Oak Ridge National Laboratory. As envisioned by Gary Steimer of the lab's National Security Directorate, the Advanced Integrated Responder Ensemble (AIRE) will be made of new materials, will be lightweight and incorporate sensors and a communications system. The suit will provide thermal protection, personal cooling and will detect and counter chemical and biological threats. "From boots to helmet, AIRE will provide first responders with technological advances that will dramatically increase their capabilities," Steimer said. Partners in the effort include the Georgia Institute of Technology, North Carolina State University and the University of Tennessee. [Contact: Ron Walli, 865-576-0226; wallira@ornl.gov]

CHEMISTRY — Self-organizing polymers . . .

By developing techniques to precisely control the growth and shape of polymers at the molecular level, researchers hope to make possible the design and synthesis of new materials with biomedical applications. The idea is to mimic the "bottoms-up" approach used in nature, which starts with single molecules of controlled size, shape and functionality, and assembles the molecules to form structures such as enzymes. Through a better understanding of these structures at the molecular level, Phil Britt of Oak Ridge National Laboratory's Chemical Sciences Division and Jimmy Mays of the University of Tennessee hope they can impact chemical, material, biological and computational sciences. Ultimately, this research could lead to targeted drug delivery systems for treating diseases.
'"/>

Contact: Ron Walli
wallira@ornl.gov
865-576-0226
DOE/Oak Ridge National Laboratory
1-Apr-2004


Page: 1 2 3

Related biology news :

1. Story tips from the Department of Energys Oak Ridge National Laboratory, September 2004
2. Story tips from the Department of Energys Oak Ridge National Laboratory, August 2004
3. Story tips from the Department of Energys Oak Ridge National Laboratory, July 2004
4. Press workshop Life, a Nobel Story
5. Story tips from the Department of Energys Oak Ridge National Laboratory, February 2004
6. Story tips from the Department of Energys Oak Ridge National Laboratory, January 2004
7. Story tips from the Department of Energys Oak Ridge National Laboratory
8. Story tips from the Department of Energys Oak Ridge National Laboratory, November 2003
9. Story tips from the Department of Energys Oak Ridge National Laboratory, September 2003
10. Science Picks-Leads, Feeds and Story Seeds (June 2003)
11. Science Picks--Leads, Feeds and Story Seeds (April 2003)

Post Your Comments:
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... -- Health eCareers, the healthcare industry,s online career hub, ... looking for the flexibility of short-term assignments through ... tool dedicated exclusively to temporary and shift work ... employers to quickly find and hire experienced professionals ... other temporary positions, eliminating the time and resources ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
Cached News: